arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IMMUCELL CORP /DE/

ICCC
$9.96 ▲ +0.12 (+1.22%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Bearish
auto_awesome

Analytical Summary

IMMUCELL CORP /DE/ faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $90.3M
Dividend Yield
Revenue Growth 11.5%
Op. Margin 26.9%
ROIC 4.8%
FCF / Share $0.25
Trailing P/E 49.8x
Price / Book 2.9x
FCF Yield 2.5%
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.19M
↑ +11.5%
Net Income Profit after all expenses
$1.83M
↑ +265.6%
Operating Margin Operating profit as % of sales
26.9%
↑ +41.6% 46th
FCF / Share Free cash flow per share
$0.25
↓ -32.8%
Long-Term Debt Long-term obligations
$8.30M
↓ -4.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
37
Returns
39
Financial Health
65
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters